Business Context and Reporting Period
Company: Ultralife Batteries, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999 (First quarter of fiscal year 2000)
Business Overview: The Company operates in four segments: Primary Batteries, Rechargeable Batteries, Technology Contracts, and Corporate. It manufactures specialty batteries for military, aerospace, and industrial applications.
Key Financial Metrics
| Metric | Q1 FY2000 (Sep 30, 1999) | Q1 FY1999 (Sep 30, 1998) |
|---|---|---|
| Revenues | $6,225,000 | $4,222,000 |
| Gross Profit | $419,000 | $288,000 |
| Gross Margin | 7% | 7% |
| Net Loss | $(1,926,000) | $(1,930,000) |
| Loss Per Share | $(0.18) | $(0.18) |
| Cash and Equivalents | $1,938,000 | $46,000 |
| Available-for-Sale Securities | $17,748,000 | $22,780,000 |
| Total Liquidity (Cash + Securities) | $19,686,000 | $22,826,000 |
| Long-Term Debt | $215,000 | $215,000 |
| Operating Cash Flow | $(2,214,000) | $(3,621,000) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 47% to a quarterly record of $6.2 million, driven primarily by a 50% increase in Primary Battery sales ($5.6 million) due to higher 9-volt lithium shipments.
- Expense Reduction: Research and Development expenses decreased 40% to $1.1 million due to a shift in resources to government contracts and a narrower focus on rechargeable programs. Selling, General, and Administrative (SG&A) expenses increased 15% to $1.5 million due to IT and insurance costs.
- Non-Recurring Items: The prior year included a $468,000 gain on fire insurance proceeds which is absent in the current period. Excluding this item, operating expenses decreased 17% year-over-year.
- Cash Position: Cash and cash equivalents increased significantly from $776,000 to $1,938,000, aided by a $3.2 million proceeds from the issuance of common stock related to a Taiwan venture.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management anticipates sales orders and production volumes will increase sufficiently in fiscal 2000 to fully absorb factory overheads in the U.K. facility. The Company is pursuing a working capital line of credit of approximately $15 million but has no commitments as of the filing date.
- Legal Proceedings:
- Class Action: A putative class action lawsuit regarding the May 1998 public offering was dismissed without prejudice in September 1999. Plaintiffs filed a Second Amended Complaint in November 1999; the outcome is uncertain and damages cannot be quantified.
- Interference Claim: An individual filed a suit claiming interference with the purchase of the Company's U.K. subsidiary, seeking $25 million. Management believes the claim is without merit.
- Environmental Contingency: An environmental assessment of the Newark, NY facility revealed contaminated soil. Estimated remediation costs are $230,000, with a third party agreeing to reimburse 50%. Total costs remain uncertain.
- Year 2000 Compliance: The Company implemented a new enterprise-wide software system in July 1999 and believes its systems are fully Year 2000 compliant. Total project costs were approximately $450,000.
Investor Verification Checklist
- Verify the status of the Second Amended Class Action Complaint filed in November 1999 and potential exposure.
- Confirm the timeline and volume targets required to absorb U.K. facility overheads as projected by management.
- Monitor the progress of the $15 million working capital line of credit negotiations.
- Review the final cost estimates for the Newark, NY soil remediation and the status of the third-party reimbursement agreement.
- Assess the performance of the new Taiwan venture (Ultralife Taiwan, Inc.) following the issuance of 700,000 shares.